An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma

Sponsor
Hoffmann-La Roche
Study ID
NCT07200375
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Glofitamab — DRUG
    Participants will receive glofitamab as part of a cancer-treatment regimen in a real-world setting. No intervention will be administered by study investigators.

Study Details

This study will investigate how well glofitamab-based therapy works and how safe it is in Chinese adult participants with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).

Key Dates

First listed
Oct 1, 2025
Start date
Sep 29, 2025
Status verified
Aug 2026
Primary completion
Sep 29, 2029
Completion
Sep 29, 2029

Study Design

Enrollment
300 participants (estimated)

Arms

  • Arm: Glofitamab treatment
    Participants will be enrolled into the study either prior to initiation of glofitamab therapy or within 90 days of starting glofitamab therapy.

Primary Outcome Measure

real-world Progression-Free Survival (rwPFS) [ Time Frame: Up to approximately 4 years ]

Central Contacts

  • Reference Study ID Number: ML45172 https://forpatients.roche.com/ No attachments to email below.
    888-662-6728 (U.S. and Canada)
    [email protected]
  • Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry

Related Studies